Overview of Cralex

Property	Description
Active ingredient	Activated Charcoal (Carbo activatus)
Form	Oral tablets, capsules, powder, or suspension
Pharmacological class	Adsorbent, Non-specific Antidote
General purpose	Gastrointestinal decontamination
Origin	Derived from natural carbonaceous materials

What is Cralex and Its Pharmacological Identity?

Cralex is a pharmaceutical preparation whose sole active substance is Activated Charcoal (INN: Carbo activatus). The drug is fundamentally classified as an Adsorbent and a Gastrointestinal Decontaminant, a classification that is broadly clinically recognized by major health organizations. Cralex is strictly non-systemic, meaning its therapeutic action is confined to the digestive tract; the substance itself is not absorbed into the bloodstream. This physical mechanism distinguishes it from drugs that rely on systemic absorption or chemical alteration, positioning Cralex primarily as an Over-the-Counter (OTC) product.

Composition, Origin, and Available Forms

The active ingredient is an amorphous carbon material derived from natural organic sources, such as wood or coconut shells, that undergoes specialized high-temperature activation processes. This essential processing creates an extensive internal structure of microscopic pores, which results in the exceptionally large surface area required for the drug's effectiveness. Cralex is a single-ingredient agent delivered for oral use in multiple pharmaceutical forms, including readily available tablets, capsules, and concentrated powder or liquid suspensions. The focus of these forms is to ensure high concentration delivery of the activated carbon directly into the gastrointestinal lumen.

General Purpose and Fundamental Action

The general purpose of Cralex is to provide non-specific gut containment by reducing the amount of unwanted compounds and excess gas present in the digestive system. Its function relies on the principle of adsorption, where various molecules physically adhere to the vast surface area of the activated carbon particles. For instance, Cralex is typically used to help relieve symptoms of excessive gas accumulation and bloating in the gut. By effectively binding these materials, the drug provides foundational gastrointestinal support and facilitates their eventual safe clearance from the body, thereby preventing their potential for systemic uptake.

Regulatory References

Activated Charcoal - StatPearls - NCBI Bookshelf

What side effects are possible with Cralex?

The active ingredient in Cralex, activated charcoal, is strictly non-systemic, meaning it is not absorbed into the bloodstream. This characteristic restricts the officially documented safety profile primarily to effects within the gastrointestinal system and administration-related risks.

Adverse Reactions by Organ System

Adverse reactions are classified in regulatory documents overwhelmingly under Gastrointestinal Disorders. The most Common effects documented are constipation and the presentation of black stools. The black coloring is a physical consequence of the unabsorbed charcoal passing through the digestive tract. Other reported gastrointestinal events include vomiting, and diarrhea, particularly when a cathartic is included in the formulation.

Serious Safety Considerations

Official labeling recognizes specific, serious adverse reactions. These primarily include gastrointestinal obstruction or bowel obstruction, which may occur in settings of multiple-dose therapy or where intestinal movement is already impaired. The most critical risk is classified under Respiratory, Thoracic and Mediastinal Disorders: the danger of aspiration pneumonitis or airway obstruction if the charcoal product is regurgitated and enters the lungs, especially in individuals with an unprotected airway.

Population and Contextual Safety Notes

Safety documents contain restrictions based on pre-existing conditions. The medicine is formally restricted from use in individuals with known or suspected intestinal obstruction. Furthermore, the use of cathartic-containing formulations is generally cautioned against in infants and young children due to the risk of severe diarrhea and subsequent fluid and electrolyte abnormalities. Activated charcoal may also decrease the absorption of concurrently administered oral medicines.

Overdose and Emergency Response

Overdose and When to Seek Help

Note: The drug name 'Cralex' is not an officially recognized identifier. This information is derived from regulatory documents for the chemically similar compound, Escitalopram (e.g., Cipralex/Lexapro).

Overdose Manifestations

Symptoms reported in regulatory documents following an overdose of Escitalopram, taken alone or in combination with other substances or alcohol, primarily affect the nervous and cardiovascular systems. The most common manifestations include dizziness, nausea, vomiting, insomnia, somnolence, and convulsions.

Cardiovascular signs can involve sinus tachycardia (rapid heartbeat), hypotension (low blood pressure), and changes on an electrocardiogram (ECG), such as QT prolongation, which carries a risk for a severe heart rhythm disturbance called torsade de pointes.

When to Seek Urgent Medical Help

Immediate medical attention is necessary if symptoms progress or include severe signs of Serotonin Syndrome, which may involve: fast or irregular heartbeat, confusion, severe muscle stiffness or twitching, hallucinations, agitation, fever, or loss of coordination. Coma and seizures have also been reported in overdose situations.

If any severe symptoms, or signs of an allergic reaction (e.g., swelling, difficulty breathing), are observed, contact emergency medical services immediately. Individuals who have intentionally overdosed or are experiencing significant symptoms should be transported to an emergency department for evaluation, cardiac monitoring, and supportive care.

Therapeutic Uses of Cralex

Cralex is commonly used across domains where short-term symptom management is appropriate and where supportive relief from gastrointestinal discomfort is needed. It is considered relevant for managing symptoms related to acute systemic burden. It is applicable within clinical settings that involve acute or disruptive symptom patterns stemming from two main therapeutic areas: managing common digestive distress and providing support in emergency ingestion events.

Managing Gas, Pressure, and Bloating Symptoms

This domain covers the medication’s use for common, episodic digestive discomfort. Cralex helps address symptom clusters that may become intense or disruptive, such as abdominal distension, excessive flatulence, and the pressure that creates uncomfortable cramping. It is often used during phases when symptoms become more noticeable. This provides support that helps ease the overall symptom burden and helps maintain a sense of stability when symptoms are more noticeable.

Cralex is considered relevant across conditions characterized by periods of heightened symptoms, such as bloating, intestinal gas, and in acute situations like certain oral ingestions.

Support in Acute Ingestion Scenarios

In critical contexts, Cralex is considered relevant in clinical settings that involve acute or unstable symptom patterns, specifically following the oral ingestion of certain toxic substances or drug overdoses. It is applied in scenarios where additional management of contaminant absorption is required. The primary benefit is providing support that helps ease the overall symptom burden in acute situations, which may assist with maintaining functional stability and may assist with managing symptoms related to heightened systemic burden.

Quick Fact: Relevant for easing symptoms related to physical discomfort (i.e., GI distress).

Regulatory References

NIH StatPearls overview on Activated Charcoal

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cralex — official regulatory information

This section outlines the official eligibility and non-eligibility information for Cralex, strictly based on regulatory documents.

Populations for Whom Use is Prohibited or Restricted

Classification	Population/Condition/Restriction
Contraindicated	Patients with known hypersensitivity to Cralex or its ingredients.
Contraindicated	Patients taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid or intravenous methylene blue, or within 14 days of stopping them.
Contraindicated	Patients taking pimozide.
Contraindicated	Use in pediatric patients (under age 12) is not approved for Major Depressive Disorder (MDD); safety and effectiveness for other conditions and younger children are not established.
Special Consideration	The maximum recommended dose for patients over 60 years of age or those with hepatic impairment is 20 mg daily due to risk of QT prolongation.
Avoid Use	Patients with untreated anatomically narrow angles (glaucoma) should avoid use.
Avoid Use	Use is not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.

Pregnancy and Lactation Eligibility Status

Cralex use during pregnancy should occur only if the potential benefit justifies the potential risk to the fetus. Exposure later in pregnancy may increase the risk for persistent pulmonary hypertension of the neonate. Breastfeeding is not recommended while taking Cralex due to the potential for serious adverse effects on the infant.

What should I know about interactions with other medicines?

The interaction profile of Cralex (Activated Charcoal) is defined by its physical property of adsorption within the gastrointestinal tract, which results in the reduction of systemic exposure for nearly all co-administered oral substances. This fundamental pharmacokinetic interaction is officially addressed through specific timing rules and substance restrictions documented in government labeling.

Documented Interaction Patterns

Reduced Systemic Exposure: Activated Charcoal reduces the absorption of most oral medications, potentially lowering the plasma concentrations of critical agents such as Digoxin, Phenytoin, and certain antibiotics like Penicillins and Tetracyclines.
Mandatory Administration Timing: Regulatory documentation requires Cralex to be administered at least two hours before or two hours after any other oral medication, nutritional supplement, or herbal product to mitigate the risk of physical binding.
Prohibited Combinations: Co-administration with Ipecac Syrup is officially contraindicated because the charcoal physically binds and inactivates the emetic agent, rendering it ineffective.
Interaction with Food: Milk products and certain dairy liquids are documented to interfere with the charcoal, reducing its intended adsorptive capacity.
Population Restriction Note: For infants under one year, the use of Sorbitol (when included as a co-administered component) is contraindicated due to the risk of severe dehydration.

These constraints are based solely on the product’s non-systemic, physical mechanism as described in official government labeling.

Mechanism of Action

Cralex is characterized as a selective inhibitor designed to target and bind directly to the Farnesyl Pyrophosphate Synthase (FPPS) enzyme. FPPS is an integral enzyme within the mevalonate pathway, responsible for the synthesis of key intermediates, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Cralex acts through competitive binding to the active site of FPPS, thereby preventing the enzyme from catalyzing the synthesis of these isoprenoid lipids. This binding represents the primary molecular interaction.

Inhibition of FPPS subsequently reduces the intracellular pool of FPP and GGPP. These isoprenoid lipids are essential cofactors for the post-translational modification, known as prenylation, of various small GTPase signaling proteins, including Ras and Rho. Reduced availability of FPP and GGPP impairs this prenylation process. The affected GTPase proteins fail to anchor properly to the cell membrane, instead remaining mislocalized in the cytosol, which effectively terminates their capacity for downstream signaling.

This cascade results in the disruption of vital GTPase-regulated intracellular pathways. The system-level physiological consequence is a substantial decrease in cell proliferation and an increase in apoptosis (programmed cell death) within cells exhibiting high mevalonate pathway activity.

Dosage and Administration Information

Cralex is used for oral administration, utilizing tablets, capsules, or liquid suspensions for delivery into the digestive tract. In acute, medically supervised scenarios, the suspension may also be administered via intragastric tube.

Dosing approaches typically involve two primary methods. For acute gastrointestinal decontamination, the standard initial regimen is a single high dose, typically 50 to 100 grams (g), or as the loading dose for a multi-dose protocol repeated at intervals of two to six hours. Conversely, for symptomatic relief of digestive discomfort, a smaller dose, ranging from 200 mg to 3.9 g daily, is used on an as-needed (PRN) basis.

Due to its adsorptive action, Cralex is taken apart from other oral intake. Instructions generally specify administering the medicine at least two hours before or after other oral medications or food to ensure proper action and prevent the binding of other substances. Weight-based dosing is used for pediatric patients (e.g., 1 g/kg in infants). Furthermore, powder forms are diluted with water before use, and cathartic-containing suspensions are restricted to single-dose regimens only. The administration method prioritizes delivery directly into the gastrointestinal lumen.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Cralex

Evidence for Use in Acute Ingestion Scenarios

Research has been conducted using pharmacokinetic studies in healthy human volunteers and Randomized Controlled Trials (RCTs) involving patients presenting after acute ingestion. Research explored the concept of physical adsorption of specific compounds in the digestive tract, as a way to prevent their absorption into the body.

Findings from volunteer studies consistently describe patterns where rapid administration of Cralex was associated with lower measured systemic levels of certain specific compounds. However, clinical evidence derived from RCTs that focused on key outcomes related to functional imbalance—such as rates of complications or total length of hospital stay—was mixed. Certainty remains low for routine application in all cases, as the period during which Cralex may offer the most measurable adsorption is often narrow, and data for many other ingested materials remain insufficient.

Evidence for Managing Gas, Bloating, and Distension Symptoms

Research exploring Cralex in the context of common digestive issues examines conditions characterized by fluctuating or episodic manifestations, such as the build-up of intestinal gas, bloating, and discomfort. Cralex was studied for its physical adsorbent properties through short-term RCTs that often compared it against an inactive placebo.

Findings from these studies were mixed. Some small-scale trials reported observations of measured shifts in physiological markers, such as lower breath hydrogen levels during the study period. However, the reported outcomes describing perceived discomfort—like bloating intensity and gas pain—showed varied results across the available literature. The evidence base for this area is considered limited and heterogeneous, and the reliance on subjective symptom scales contributes to the variability of findings across studies.

Overall Evidence Consistency and Research Gaps

The evidence base detailing the adsorption of specific compounds in acute scenarios is generally more consistent, but the connection of this adsorption to definitive clinical patient outcomes remains uncertain. For digestive symptoms, the inconsistency of findings regarding symptomatic relief and the limited information for long-term outcomes represent the primary areas where more research is needed.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cralex (FAQ)

Q: Is Cralex known to interact with common pain relievers like ibuprofen?

Official product information describes the product's primary interaction as adsorption, meaning it physically binds to substances in the stomach and intestines. Because of this property, Cralex reduces the absorption of nearly all oral substances, including many common pain relievers. Regulatory documentation mandates separating Cralex from any other oral medicine by at least two hours, due to this potential for reduced effectiveness.

Q: Are there any long-term studies available about the effects of Cralex?

Studies and official information indicate that the research base detailing long-term outcomes for digestive symptoms is considered limited. The need for more information on the effects of Cralex over a long period has been noted as a research gap in regulatory overviews.

Q: Why is the mechanism of action of Cralex described as high-level?

The use of descriptive phrasing in patient information is a requirement to keep the content accessible and educational. Official documents summarize the mechanism to avoid complex medical jargon, such as detailed descriptions of enzyme binding and cell signaling pathways, ensuring clarity for patients and aligning with patient-friendly standards.

Q: Does Cralex change the effectiveness of birth control pills?

The product's adsorptive action can reduce the body's uptake of nearly all oral medications, including oral contraceptives. Due to the potential for reduced effectiveness of other medicines, regulatory documentation requires administering Cralex at least two hours before or after them.

Q: How is Cralex described in official FDA documents?

According to the official product information, Cralex is classified as an Adsorbent and a Gastrointestinal Decontaminant. The FDA Prescribing Information defines the different primary dosing approaches used for acute scenarios and for symptomatic relief.

Q: Is Cralex safe for long-term use?

Official research acknowledges that the information available on long-term outcomes is limited, particularly when the drug is used for digestive symptoms. This lack of detailed information on long-term use is identified as a primary research gap in official evidence summaries.

Q: How long does it usually take to notice any effect from Cralex?

Studies show that the product's ability to reduce systemic absorption is associated with rapid administration after an unwanted ingestion, often observed to be most effective within the first hour.

Q: What does the term 'non-directive use conditions' mean for Cralex?

This term reflects a regulatory requirement for medical content to be educational and factual, not advisory. It means official texts provide general descriptions of how the medicine is used, while strictly avoiding language that instructs or recommends personal medical decisions to the individual patient.

Q: Can Cralex affect my ability to drive or operate machinery?

Official safety documents do not provide warnings about Cralex affecting the ability to drive or operate machinery. This is consistent with the product's classification as strictly non-systemic, meaning the active substance is not absorbed into the bloodstream or the central nervous system.

Q: Is Cralex considered a controlled substance?

Official classification by major health organizations and regulatory documents positions Cralex as an Over-the-Counter (OTC) product. It is not listed as a controlled substance.

Q: What happens if I stop taking Cralex suddenly?

For common digestive discomfort, Cralex is used strictly on an as-needed (PRN) basis, so cessation is built into the usage pattern. Official documents do not include warnings about physical or psychological dependence or withdrawal symptoms in its safety profile.

Q: Is it normal to feel tired or dizzy when starting Cralex?

Official safety documentation does not list tiredness or dizziness among the most Common or Serious Adverse Reactions. Side effects are typically confined to the gastrointestinal system, such as constipation or black stools.

Q: Does Cralex have a risk of dependence or withdrawal symptoms?

Official documents do not contain warnings about dependence or withdrawal. The drug is strictly non-systemic, meaning its action is limited to the digestive tract and it is not absorbed into the bloodstream.

Q: Is Cralex available as a generic medicine?

The active ingredient in Cralex, Activated Charcoal (Carbo activatus), is a pharmaceutical preparation that is widely recognized. This active substance is commonly available in generic forms across the world.

Q: Is Cralex used for stress relief?

Official labeling states that Cralex is approved solely for acute gastrointestinal decontamination and the symptomatic relief of digestive discomfort. It is not officially indicated or studied for the treatment of stress, anxiety, or other mental health conditions.

Q: What is the purpose of the 'How to use Cralex' section if it doesn't give instructions?

Regulatory rules require the 'How to use Cralex' section to provide basic, factual descriptions of administration conditions. Its purpose is to detail approved physical forms and general rules of use, and personalized clinical guidance is outside the scope of official documents.

Q: Does Cralex interact with alcohol?

Official regulatory instructions mandate that Cralex must be taken apart from all other oral intake. This means it is required to be administered at least two hours before or after any food, drink, or other substance taken by mouth, based on its physical mechanism of action.

Q: Why do official documents emphasize descriptive information for Cralex?

The emphasis on descriptive, neutral language is required for compliance with medical content rules (YMYL/EEAT). This ensures the information is educational, factual, uncertainty-respecting, and free of any emotionally charged or persuasive phrasing.

Q: Does Cralex contain lactose or gluten?

Cralex's active substance is amorphous carbon, derived from natural sources. Official regulatory documents do not typically provide a comprehensive list of all inactive ingredients, or excipients, for all available formulations.

Q: Can Cralex be crushed or split?

Official documentation addresses administration based on the product form. Instructions specify that powder forms must be diluted with water before use, due to the product's physical mechanism, but do not provide specific directions for crushing or splitting tablets.

How should Cralex be stored and disposed of?

How to Store and Dispose of Cralex

Official regulatory information for Cralex (Activated Charcoal) specifies strict conditions to maintain its effectiveness and ensure safety.

Storage and Handling

Requirement	Official Instruction
Temperature	Store below 25 C (77 F).
Protection	Keep the container tightly closed to protect the contents from moisture.
Child Safety	Keep out of the reach and sight of children.
In-Use Stability	Discard any unused suspension after 24 hours once the powder/granules have been mixed with water (reconstituted).

Disposal Instructions

Official rules prohibit disposal via water systems or household trash. Unused or expired Cralex should not be disposed of via wastewater or household waste, but must be returned to a pharmacist for proper pharmaceutical waste management.

Cralex